Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Three new randomized trials presented at the ESC Congress delivered a mixed verdict on catheter ablation for atrial fibrillation. The headline PVI-SHAM-AF trial found that pulmonary vein isolation did not significantly improve quality of life over a sham procedure, though it did reduce Afib recurrence. Meanwhile, low-voltage zone ablation showed promise, while adding posterior wall isolation offered no significant benefit.
Three randomized trials presented at the European Society of Cardiology (ESC) Congress delivered a nuanced picture of catheter ablation for atrial fibrillation (Afib). The headline PVI-SHAM-AF trial — published simultaneously in The Lancet — found that pulmonary vein isolation (PVI) did not significantly outperform a sham procedure in improving Afib-related quality of life at 6 months. Notably, both groups were cardioverted if they were in Afib during the procedure, meaning the sham included an active rhythm-control step, which likely narrowed the gap between groups.
That said, PVI did meaningfully reduce Afib recurrence and Afib burden, suggesting objective rhythm benefits remain real even if patient-reported quality of life didn't separate. Experts note that the trial's relatively high baseline quality-of-life scores may have limited the room for ablation to show a differential effect. The other two trials rounded out the picture: IDEAL-AF showed that adding individualized low-voltage zone ablation to PVI significantly improved arrhythmia-free outcomes in patients with atrial fibrosis, while PIFPAF-PFA found that adding posterior left atrial wall isolation did not significantly reduce arrhythmia recurrence.
By the Numbers:
Why it matters: These trials push cardiologists to be more precise about who benefits from ablation and how — moving the field toward individualized, mapping-guided strategies rather than one-size-fits-all approaches.
